Ablacon careers

Ablamap, a revolutionary patent pending technology to identify sources of arrhythmias like atrial fibrillation during an intracardial electrophysiological examination. Not yet approved by the FDA. We expect FDA approval through 510K and market entry in the US within less than 24 months.

Ablasense, the first fully digital force sensing technology for ablation catheters to treat atrial fibrillation by RF ablation under contact force monitoring. Not yet approved by the FDA. Partnering discussions with market leading companies in process.